share_log

Janux Announced Updated Interim Clinical Data For JANX007 Clinical Program

Benzinga ·  Dec 2 13:31
  • Emerging JANX007 data demonstrated substantial clinical activity in 5L mCRPC patients, supporting clinical development plan directed at pre-PLUVICTO 2L / 3L patients
  • In 16 patients JANX007 displayed:
    • High PSA response rates: 100% achieved best PSA50 declines
    • Deep PSA declines: 63% achieved best PSA90 declines; 31% achieved best PSA99 declines
    • Durable PSA response at ≥ 12 weeks: 75% maintained PSA50 declines; 50% maintained PSA90 declines
    • Encouraging anti-tumor activity: 50% ORR (4/8) and 63% DCR (5/8)
    • Well-tolerated safety profile: CRS and TRAEs primarily limited to cycle 1 and grades 1 and 2; Maximum tolerable dose has not yet been reached
  • Janux to host virtual investor event today at 4:30 PM Eastern Time
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment